Nanology – Advancing Intratumoral Drug Therapy
  • About
    • Overview
    • Team & Advisors
    • Partnering Opportunities
  • Technology
  • Development
    • Products
    • Pipeline
    • Clinical Programs
    • Immunogenic Effect
    • Partnering Opportunities
  • News & Publications
  • Contact
    • Partnering Opportunities
    • Physicians and Patients
logo

Archive for the NanOlogy in the News Category

OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

On September 16, 2021   /   NanOlogy in the News  
Back to Top

Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC

On September 16, 2021   /   NanOlogy in the News  
Back to Top

JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy

On March 26, 2021   /   NanOlogy in the News, Uncategorized  
Back to Top

Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

On January 9, 2020   /   NanOlogy in the News  
Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

Back to Top

Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial

On May 7, 2019   /   NanOlogy in the News  
Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
Back to Top

NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

On January 11, 2019   /   Home Page, NanOlogy in the News  
NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
Back to Top

Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy

On November 6, 2018   /   Home Page, NanOlogy in the News  
Wuxi  AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
Back to Top

Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm

On August 29, 2018   /   NanOlogy in the News  
Back to Top

Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug

On May 30, 2018   /   NanOlogy in the News  
Back to Top

Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

On May 3, 2018   /   NanOlogy in the News  
Back to Top

BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy

On April 9, 2018   /   NanOlogy in the News  
Back to Top

Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform

On March 5, 2018   /   NanOlogy in the News  
Back to Top

Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery

On February 28, 2018   /   NanOlogy in the News  
Back to Top

DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases

On February 14, 2018   /   NanOlogy in the News  
Back to Top

Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference

On February 5, 2018   /   NanOlogy in the News  
Back to Top

PharmaVOICE: Next-Generation Nanomedicines

On January 3, 2018   /   NanOlogy in the News  
Back to Top

Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials

On December 19, 2017   /   NanOlogy in the News  
Back to Top

Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects

On November 20, 2017   /   NanOlogy in the News  
Back to Top

DDNEWS: New Cancer Answer

On November 13, 2017   /   NanOlogy in the News  
Back to Top

Ovarian Cancer News: First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery

On October 16, 2017   /   NanOlogy in the News  
Back to Top
Page 1 of 212»

Recent Nanology News

  • DDW 2023 Poster: Intracystic Injection of Large Surface Area Microparticle Paclitael for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol May 25, 2023
  • June 2 : 9th Annual Immuno-Oncology Innovation Forum | Chicago April 10, 2023
  • June 2-6 : ASCO 2023 – American Society of Clinical Oncology | Chicago April 10, 2023
  • August 24-26 : AABIP – 6th Annual Conference of American Association for Bronchial and Interventional Pulmonology | Chicago April 10, 2023
  • September 27-30 : AACR Special Conference: Pancreatic Cancer | Boston April 10, 2023

Home
About
Technology
Development
News & Publications
Contact

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.

© 2017-23 NanOlogy LLC     Legal
Back to Top
This website uses cookies to improve your experience. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit the Cookie Settings to provide a controlled consent. Cookie settings ACCEPT
Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

This is an necessary category.

Non Necessary

This is an non-necessary category.

Save & Accept